Brilinta is an antiplatelet drug mainly used for thrombosis prevention in patients with acute coronary syndrome. Its medication should strictly follow the indications and pay attention to key issues such as bleeding risk monitoring and drug interaction management. The following is a hierarchical explanation based on the scope of indications and clinical precautions.

1 Scope of indications

(1) Acute coronary syndrome is suitable for thrombosis prevention in adult patients with acute coronary syndrome (unstable angina, non ST segment elevation myocardial infarction, or ST segment elevation myocardial infarction), and should be combined with aspirin.

(2) Percutaneous coronary intervention therapy

Used for patients undergoing percutaneous coronary intervention (PCI) to reduce the risk of stent thrombosis, the recommended course of treatment is usually 12 months.

2 Medication precautions

(3) Bleeding risk management requires monitoring of bleeding signs (such as bruising and black stools) during medication, and is contraindicated for patients with severe active bleeding. The necessity of discontinuing medication should be evaluated before surgery, usually 5-7 days in advance.

(4) Drug interactions

Avoid using potent CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) in combination, as they may affect the efficacy of the drug. The dosage of aspirin should be controlled between 75-100mg/day to reduce the risk of bleeding.

(5) Medication for special populations

Not recommended for patients with moderate to severe liver injury; Elderly people do not need to adjust the dosage, but need to strengthen monitoring; Use with caution during pregnancy only when the benefits are clear.

(6) Adverse reaction response

If there is difficulty breathing (with an incidence rate of about 13-18%), medication usually does not need to be stopped; Persistent symptoms require assessment of lung function. Patients with bradycardia need to monitor their heart rate and adjust concomitant medications if necessary.